Veracyte (NASDAQ: VCYT) reported Q4 EPS of ($0.24), $0.04 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $19.6 million versus the consensus estimate of $18.96 million.

Fourth Quarter and Full-Year 2017 Financial Results

For the three- and twelve-month periods ended December 31, 2017, compared to the prior year:

• Revenue was $19.6 million and $72.0 million, respectively, an increase of 7% and 11%;
• Genomic Volume was 7,153 and 26,026 reported tests, respectively, an increase of 13% and 12%;
• Gross Margin was 60% and 61%, respectively, a decline of 4% and flat to prior year;
• Operating Expenses, Excluding Cost of Revenue, were $17.9 million and $70.3 million, respectively, an increase of 16% and 3%;
• Net Loss and Comprehensive Loss was ($8.4) million and ($31.0) million, respectively, an increase of 92% and decrease of 1%;
• Basic and Diluted Net Loss Per Common Share was ($0.24) and ($0.91), respectively, an increase of 71% and decrease of 17%;
• Cash Burn1 was $6.1 million and $25.2 million, respectively, an increase of 31% and improvement of 22%; and
• Cash and Cash Equivalents was $33.9 million at December 31, 2017.

GUIDANCE:

Veracyte sees FY2018 revenue of $81-83 million, versus the consensus of $84.95 million.

For earnings history and earnings-related data on Veracyte (VCYT) click here.